# Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

> **NCT06059495** · PHASE2 · RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 59 (estimated)

## Conditions studied

- Adenocarcinoma - GEJ
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT06059495
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-18
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06059495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06059495, "Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06059495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*